Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Assessment of grading in newly-diagnosed glioma using 18F-fluorothymidine PET/CT

E. Ferdová, J. Ferda, J. Baxa, R. Tupý, J. Mraček, O. Topolčan, O. Hes,

. 2015 ; 35 (2) : 955-9.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15022821

AIM: To evaluate the proliferation activity in gliomas using 18F-fluorothymidine (18F-FLT)-positron emission tomography/computed tomography (PET/CT). PATIENTS AND METHODS: Samples of 26 tumors were analyzed (mean age=51.6; range=26-72 years; 16 males, 10 females). All examinations were performed using a PET/CT scanner equipped with lutetium oxyorthosilicate (LSO) detectors. All data were acquired with a delay of 15 min, following intravenous application of 18F-FLT (dosed 2 MBq/kg of body weight). The PET/CT contained CT after intravenous application of iodinated contrast agent and high-resolution brain PET acquired during 15 min in one position. PET/CT was performed before confirmation of the histological diagnosis and the level of 18F-FLT accumulation was compared to the grading of the tumor evaluated using immunohistochemistry staining of Ki-67. Samples were obtained by stereotactic biopsy (5×) or surgical resection (21×). RESULTS: Five tumors of grade IV, 7 tumors of grade III and 14 tumors of grade II were found. Pre-bioptical discrimination between high-grade and low-grade tumors reached accuracy 92.3% (24/26), sensitivity 92.3% (12/13) and specificity 92.9 (13/14). The mean maximum standardized uptake value (SUVmax) in high-grade tumors was 2.23, significantly different from low-grade tumors (mean SUVmax 0.61, T=7.803, p<0.0001). CONCLUSION: 18F-FLT-PET/CT enables to estimate the proliferation activity of glioma before biopsy.

000      
00000naa a2200000 a 4500
001      
bmc15022821
003      
CZ-PrNML
005      
20150724120256.0
007      
ta
008      
150709s2015 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)25667480
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Ferdová, Eva $u Clinic of Imaging Methods, University Hospital Plzen, Plzeň, Czech Republic.
245    10
$a Assessment of grading in newly-diagnosed glioma using 18F-fluorothymidine PET/CT / $c E. Ferdová, J. Ferda, J. Baxa, R. Tupý, J. Mraček, O. Topolčan, O. Hes,
520    9_
$a AIM: To evaluate the proliferation activity in gliomas using 18F-fluorothymidine (18F-FLT)-positron emission tomography/computed tomography (PET/CT). PATIENTS AND METHODS: Samples of 26 tumors were analyzed (mean age=51.6; range=26-72 years; 16 males, 10 females). All examinations were performed using a PET/CT scanner equipped with lutetium oxyorthosilicate (LSO) detectors. All data were acquired with a delay of 15 min, following intravenous application of 18F-FLT (dosed 2 MBq/kg of body weight). The PET/CT contained CT after intravenous application of iodinated contrast agent and high-resolution brain PET acquired during 15 min in one position. PET/CT was performed before confirmation of the histological diagnosis and the level of 18F-FLT accumulation was compared to the grading of the tumor evaluated using immunohistochemistry staining of Ki-67. Samples were obtained by stereotactic biopsy (5×) or surgical resection (21×). RESULTS: Five tumors of grade IV, 7 tumors of grade III and 14 tumors of grade II were found. Pre-bioptical discrimination between high-grade and low-grade tumors reached accuracy 92.3% (24/26), sensitivity 92.3% (12/13) and specificity 92.9 (13/14). The mean maximum standardized uptake value (SUVmax) in high-grade tumors was 2.23, significantly different from low-grade tumors (mean SUVmax 0.61, T=7.803, p<0.0001). CONCLUSION: 18F-FLT-PET/CT enables to estimate the proliferation activity of glioma before biopsy.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádory mozku $x patologie $x radiografie $x radioizotopová diagnostika $7 D001932
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluorodeoxyglukosa F18 $x diagnostické užití $7 D019788
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multimodální zobrazování $7 D064847
650    _2
$a pozitronová emisní tomografie $7 D049268
650    _2
$a počítačová rentgenová tomografie $7 D014057
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ferda, Jiří $u Clinic of Imaging Methods, University Hospital Plzen, Plzeň, Czech Republic ferda@fnplzen.cz.
700    1_
$a Baxa, Jan $u Clinic of Imaging Methods, University Hospital Plzen, Plzeň, Czech Republic.
700    1_
$a Tupý, Radek $u Clinic of Imaging Methods, University Hospital Plzen, Plzeň, Czech Republic.
700    1_
$a Mraček, Jan $u Department of Neurosurgery, University Hospital Plzen, Plzeň, Czech Republic.
700    1_
$a Topolčan, Ondřej $u Immunoanalytic Laboratory, University Hospital Plzen, Plzeň, Czech Republic.
700    1_
$a Hes, Ondrej $u Sikl's Institute of Pathological Anatomy, University Hospital Plzen, Plzeň, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 35, č. 2 (2015), s. 955-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25667480 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150724120336 $b ABA008
999    __
$a ok $b bmc $g 1083160 $s 905814
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 35 $c 2 $d 955-9 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Možnosti archivace